<DOC>
	<DOCNO>NCT00386165</DOCNO>
	<brief_summary>To demonstrate safety tolerance single , oral dos AT-1001 celiac disease subject gluten-free diet remission .</brief_summary>
	<brief_title>Safety Study AT1001 Treat Celiac Disease .</brief_title>
	<detailed_description>One ( 1 ) cohort 24 ( 2:1 drug : placebo ) subject receive single oral dos either AT-1001 matching placebo . Subjects complete screen thereafter admit clinic prior treatment . On Day 1 AT-1001 match placebo administer followed baseline intestinal permeability test . Intestinal permeability measure administration oral sucrose , lactulose mannitol solution follow 8-hour urine collection . Day 2 subject give AT-1001 match placebo follow gluten challenge intestinal permeability test repeat . Day 3 subject administer AT-1001 match placebo follow post gluten challenge intestinal permeability test . Serial blood sample collect pharmacokinetic determination baseline , 2 , 3 hour post administration AT-1001 match placebo , zonulin determination baseline ( prior first dose ) 3 hour post dose , cytokine determination baseline , 3 hour post dose ( Days 2 3 ) Day 7 . Sucrose , lactulose , mannitol , zonulin AT-1001 concentration determine validated analytical method . Subjects evaluate screening ( medical history , physical examination , vital sign , clinical laboratory testing , 12-lead electrocardiogram ) . Vital sign clinical laboratory test conduct pre-dose vital sign , clinical laboratory test EKG monitor post dose . Adverse event report monitor throughout study . At end study physical exam clinical laboratory test perform .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Subject must diagnose celiac disease biopsy ≥ 6 month ( attend physician confirmation accept lieu biopsy report ) . Subject must glutenfree diet least past 6 month . Subject AntiTissue Transglutaminase ( tTG ) &gt; 10 EU measure serology Subject intermittently consume clinically significant quantity nonsteroidal antiinflammatory agent ( “ NSAIDs ” ) protonpump inhibitor , within last 3 day prior treatment visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>